Podium Presentation in Room 3 on Thursday at 11:00 (Chair: Chris Cox)
Authors: Chris Cox
Clinical microbiology has been revolutionized by mass spectrometry, which has dramatically improved accuracy and overall performance in the diagnostic laboratory for microbial identification. More recently, mass spectrometry is also being used to confront the increasing problem of antibiotic resistance. How does it all work? What are the challenges, successes and failures driving this exciting and rapidly expanding area of clinical mass spectrometry? We invite you to join in an overview and discussion that will describe the practical application of current approaches and explore emerging new technologies.
Significant leaps forward. Microbial protein profiling by MALDI-TOF MS has achieved widespread adoption because it allows rapid identification of bacteria, mycobacteria, yeast, and molds, in less time and at less cost than conventional methods. FDA- cleared, benchtop MALDI TOF instruments from Bruker and bioMéreiux have transformed microbial diagnostics from a collection of laborious tests requiring several days into a streamlined process accomplished in only hours. Find out how these approaches are drastically shortening testing times and significantly improving patient outcomes.
Mass spectrometry at the cutting edge. New approaches are enabling mass spectrometric diagnosis with even greater accuracy while also allowing for genotypic and phenotypic antibiotic resistance determination. What are these new technologies and how can they be brought to bear on the increasingly lethal superbugs impacting human health?
|Board Member||yes||MSACL Scientific Committee|
|Planning to mention or discuss specific products or technology of the company(ies) listed above:||